Qurratul Ann Warsi

No ORCID on file · 7 papers in corpus · active 2020-2022

Study types

  • article 7

Condition tags

  • endometriosis 7
  • dysmenorrhea 3
  • mesh:D004715 1
  • mesh:D017699 1
  • dyspareunia 1
  • mesh:D004412 1
article 2022
Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)
Lancet (London, England) ·doi:10.1016/s0140-6736(22)00622-5

BACKGROUND: Endometriosis is a common cause of pelvic pain in women, for which current treatment options are suboptimal. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, combined with estradiol and a progestin, was eva…

article 2021
O-131 The effect of time since surgical diagnosis of endometriosis on treatment outcomes with relugolix combination therapy in women with endometriosis-associated pain: SPIRIT program
·doi:10.1093/humrep/deab126.056

Abstract Study question To assess the efficacy of Relugolix-CT vs placebo in women who were surgically diagnosed with endometriosis <5 and > = 5 years ago. Summary answer Treatment outcomes did not differ for dysmenorrhea and daily fu…

article 2021
O-132 Sustained efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT 52-week data
·doi:10.1093/humrep/deab126.057

Abstract Study question To assess the long-term (52-week) efficacy and safety of relugolix combination therapy (Relugolix-CT) in the treatment of endometriosis-associated pain. Summary answer Relugolix-CT demonstrated a sustained improvemen…

article 2021
RELUGOLIX COMBINATION THERAPY IMPROVES MULTIPLE DIMENSIONS OF QUALITY OF LIFE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: RESULTS FROM THE SPIRIT PROGRAM
·doi:10.1016/j.fertnstert.2021.07.146
article 2021
Sustained Efficacy and Safety of Relugolix Combination Therapy in Women with Endometriosis-Associated Pain: Spirit 52-Week Data
·doi:10.1016/j.jmig.2021.09.031
article 2021
The Effect of Time Since Surgical Diagnosis of Endometriosis on Treatment Outcomes with Relugolix Combination Therapy: Spirit Program
·doi:10.1016/j.jmig.2021.09.032
article 2020
EFFICACY AND SAFETY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (SPIRIT 2)
·doi:10.1016/j.fertnstert.2020.08.238